2012 focused update of the ESC Guidelines for the management of atrial fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillationDeveloped with the special contribution of the European Heart Rhythm Association, Eur Heart J, vol.33, issue.21, pp.2719-2766, 2012. ,
New Antithrombotic Drugs, Chest, vol.141, issue.2, pp.120-151, 2012. ,
DOI : 10.1378/chest.11-2294
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278067
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-?NOVATE II*). A randomised, double-?blind, non-?inferiority trial ,
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty, New England Journal of Medicine, vol.358, issue.26, pp.2765-75, 2008. ,
DOI : 10.1056/NEJMoa0800374
URL : http://mediatum.ub.tum.de/doc/693767/document.pdf
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, The Lancet, vol.372, issue.9632, pp.31-40, 2008. ,
DOI : 10.1016/S0140-6736(08)60880-6
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement, New England Journal of Medicine, vol.363, issue.26, pp.2487-98, 2010. ,
DOI : 10.1056/NEJMoa1006885
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial, The Lancet, vol.375, issue.9717, pp.807-822, 2010. ,
DOI : 10.1016/S0140-6736(09)62125-5
Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009. ,
DOI : 10.1056/NEJMoa0905561
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011. ,
DOI : 10.1056/NEJMoa1009638
URL : https://hal.archives-ouvertes.fr/hal-01038111
Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-92, 2011. ,
DOI : 10.1056/NEJMoa1107039
Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, vol.363, issue.26, pp.2499-510, 2010. ,
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism, New England Journal of Medicine, vol.366, issue.14, pp.1287-97, 2012. ,
DOI : 10.1056/NEJMoa1113572
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2342-52, 2009. ,
DOI : 10.1056/NEJMoa0906598
URL : https://hal.archives-ouvertes.fr/ujm-00439704
Oral Apixaban for the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.369, issue.9, pp.799-808, 2013. ,
DOI : 10.1056/NEJMoa1302507
URL : https://hal.archives-ouvertes.fr/hal-00932477
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis, European Heart Journal, vol.34, issue.22, pp.1670-80 ,
DOI : 10.1093/eurheartj/eht049
Potential role of rivaroxaban in patients with acute coronary syndrome, Drug Design, Development and Therapy, 2012. ,
DOI : 10.2147/DDDT.S30342
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients, New England Journal of Medicine, vol.368, issue.6, pp.513-536, 2013. ,
DOI : 10.1056/NEJMoa1111096
URL : https://hal.archives-ouvertes.fr/hal-00933269
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients, New England Journal of Medicine, vol.365, issue.23, 2011. ,
DOI : 10.1056/NEJMoa1110899
URL : https://hal.archives-ouvertes.fr/hal-00721937
Disponible: http://insee.fr/fr/themes/document, la croissance retrouvée des espaces ruraux reste limitée à sept régions [Internet]. [consulté le 10 Octobre 2014]asp?reg_id=17&ref_id=15862&page=EL/EL205-? 206/EL205-?206_4.htm 28. EDO sophie. Etude comparative des conditions de vie et d'exercice des femmes médecins généralistes en milieu urbain, semi-?urbain et rural en Isère. Faculté de medecine Lyon sud Charles Merieux, 2010. ,
Management of major bleeding complications and emergency surgery in patients on long-?term treatment with direct oral anticoagulants, thrombin or factor-?Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) -? Ann Fr Anesthèsie Rèanimation, pp.691-700, 2013. ,
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in??vitro study, Journal of Thrombosis and Haemostasis, vol.8, issue.1, 2011. ,
DOI : 10.1111/j.1538-7836.2010.04106.x
Assessment of laboratory assays to measure rivaroxaban ??? an oral, direct factor Xa inhibitor, Thrombosis and Haemostasis, vol.103, issue.4, pp.815-840, 2010. ,
DOI : 10.1160/TH09-03-0176
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model, Critical Care, vol.18, issue.1, p.27, 2014. ,
DOI : 10.1093/bja/aes502
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4 ,
DOI : 10.1038/nm.3102
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects, Circulation, vol.124, issue.14, pp.1573-1582, 2011. ,
DOI : 10.1161/CIRCULATIONAHA.111.029017
Recombinant Factor VIIa to Manage Major Bleeding from Newer Parenteral Anticoagulants, Annals of Pharmacotherapy, vol.44, issue.4, pp.718-744, 2010. ,
DOI : 10.1345/aph.1M447
New oral anticoagulants in elderly patients, Best Practice & Research Clinical Haematology, vol.26, issue.2, pp.215-239 ,
DOI : 10.1016/j.beha.2013.07.011
Efficacy and Safety of Dabigatran Etexilate and Warfarin in ???Real-World??? Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.61, issue.22, pp.2264-73, 2013. ,
DOI : 10.1016/j.jacc.2013.03.020
Bleeding risk with dabigatran in the frail elderly, NEJM N Engl J Med. 2012, vol.366, issue.9, pp.864-870 ,
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study, BMJ Open, vol.3, issue.9, p.3343, 2013. ,
DOI : 10.1136/bmjopen-2013-003343
Les anticoagulants oraux directs (AOD) (antérieurement appelés " nouveaux anticoagulants oraux " ou NACO) Académie Nationale de Médecine, 2014. ,
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0???1: A nationwide cohort study, Thrombosis and Haemostasis, vol.107, issue.6, 2012. ,
DOI : 10.1160/TH12-03-0175
The management of oral anticoagulant therapy: the patient's point of view, Thromb Haemost, vol.83, issue.1, pp.49-53, 2000. ,
The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Archives of Internal Medicine, vol.151, issue.10, pp.1944-1953, 1991. ,
DOI : 10.1001/archinte.151.10.1944
Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?, Journal of Thrombosis and Haemostasis, vol.17, issue.2, pp.390-394, 2013. ,
DOI : 10.1111/jth.12086
Effect of Study Setting on Anticoagulation Control, Chest, vol.129, issue.5, 2006. ,
DOI : 10.1378/chest.129.5.1155
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range, Circulation, vol.118, issue.20, pp.2029-2066, 2008. ,
DOI : 10.1161/CIRCULATIONAHA.107.750000
A systematic review of the associations between dose regimens and medication compliance, Clinical Therapeutics, vol.23, issue.8, pp.1296-310, 2001. ,
DOI : 10.1016/S0149-2918(01)80109-0
New oral anticoagulants in primary care: The general practitioner's point of view]. Presse Médicale Paris Fr 1983, pp.1267-73, 2013. ,
Les médecins face aux nouveaux anticoagulants. [DES de médecine générale], 2013. ,
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients, Current Medical Research and Opinion, vol.30, issue.7, pp.1317-1342 ,
DOI : 10.1185/03007995.2014.907140
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN), American Heart Journal, vol.163, issue.6, pp.931-938 ,
DOI : 10.1016/j.ahj.2012.03.011
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses, BMJ, vol.343, issue.oct31 1, p.6333, 2011. ,
DOI : 10.1136/bmj.d6333
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation, PharmacoEconomics, vol.132, issue.3, pp.601-613, 2014. ,
DOI : 10.1007/s40273-014-0152-z
Dabigatran: how the drug company withheld important analyses, BMJ, vol.349, issue.jul23 12, p.4670, 2014. ,
DOI : 10.1136/bmj.g4670
A general practitioner's one year record of adverse drug reactions ,
Rapport sur la pharmacovigilance et gouvernance de la chaîne du médicament. Inspection générale des affaires sociales, Juin, 2011. ,
Patient versus Healthcare Professional Spontaneous Adverse Drug Reaction Reporting, Drug Safety, vol.33, issue.462, pp.807-825, 2012. ,
DOI : 10.1007/BF03261977